Ekso Bionics (EKSO) Stock Price, News & Analysis

Company Overview

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions. These devices are utilized in hospitals and rehabilitation centers across North America and Europe, enabling physical therapists to deliver overground gait training with customizable robotic support and integrated performance tracking.

On the industrial side, EksoWorks exoskeletons—including the EksoVest and EksoZeroG—help reduce workplace fatigue and lower the risk of musculoskeletal injuries in manufacturing, warehousing and automotive assembly. By offloading weight and supporting the arms or torso, these wearable solutions improve ergonomics, enhance worker safety and boost productivity in environments that involve repetitive overhead or lifting tasks.

Ekso Bionics serves a global customer base spanning the United States, Europe and Asia. The company’s leadership team, led by Chief Executive Officer Paul R. Sandner, brings together expertise in robotics, biomechanics and healthcare to drive ongoing innovation and expand market adoption of wearable robotics technologies.

Key Stats

• Today's Range: $4.91 to $5.10
• 50-Day Range: $2.98 to $5.60
• 52-Week Range: $2.73 to $17.32
• Volume: 27,683 shs
• Average Volume: 63,035 shs
• Market Capitalization: $12.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $562.50
• Consensus Rating: Hold

Ekso Bionics Stock Analysis - MarketRank™

Ekso Bionics scored higher than 60% of companies evaluated by MarketBeat, and ranked 414th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Ekso Bionics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Ekso Bionics has a consensus price target of $562.50, representing about 11,286.6% upside from its current price of $4.94.

Amount of Analyst Coverage

Ekso Bionics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ekso Bionics are expected to grow in the coming year, from ($0.48) to ($0.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ekso Bionics is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ekso Bionics is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ekso Bionics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.79% of the float of Ekso Bionics has been sold short.

Short Interest Ratio / Days to Cover

Ekso Bionics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ekso Bionics has recently decreased by 13.19%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ekso Bionics does not currently pay a dividend.

Dividend Growth

Ekso Bionics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.79% of the float of Ekso Bionics has been sold short.

Short Interest Ratio / Days to Cover

Ekso Bionics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ekso Bionics has recently decreased by 13.19%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.95

News Sentiment

Ekso Bionics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Ekso Bionics this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Ekso Bionics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ekso Bionics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.10% of the stock of Ekso Bionics is held by insiders.

Percentage Held by Institutions

Only 6.42% of the stock of Ekso Bionics is held by institutions.

EKSO Stock Analysis - Frequently Asked Questions

How have EKSO shares performed this year?

Ekso Bionics' stock was trading at $137.25 at the start of the year. Since then, EKSO shares have decreased by 96.4% and is now trading at $4.94.

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) issued its quarterly earnings data on Monday, July, 28th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $0.04. The firm earned $2.06 million during the quarter, compared to analyst estimates of $4.31 million. Ekso Bionics had a negative net margin of 75.66% and a negative trailing twelve-month return on equity of 86.60%.
Read the conference call transcript.

When did Ekso Bionics' stock split?

Shares of Ekso Bionics reverse split on Tuesday, May 27th 2025.The 1-15 reverse split was announced on Monday, May 19th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Ekso Bionics?

Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ekso Bionics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ekso Bionics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), TransEnterix (TRXDW), Meta Platforms (META), Tesla (TSLA), Editas Medicine (EDIT) and Micron Technology (MU).

Company Calendar

• Last Earnings: 7/28/2025
• Today: 10/13/2025
• Next Earnings (Estimated): 10/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Machinery
• Current Symbol: NASDAQ:EKSO
• Previous Symbol: OTCMKTS:EKSOD
• CIK: 1549084
• Web: www.eksobionics.com
• Phone: (510) 984-1761
• Fax: 510-927-2647
• Employees: 60
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Ekso Bionics: $562.50
• High Price Target: $900.00
• Low Price Target: $225.00
• Potential Upside/Downside: +11,114.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.33 million
• Net Margins: -75.66%
• Pretax Margin: -75.66%
• Return on Equity: -86.60%
• Return on Assets: -41.70%

Debt

• Debt-to-Equity Ratio: 0.31
• Current Ratio: 2.38
• Quick Ratio: 1.57

Sales & Book Value

• Annual Sales: $14.65 million
• Price / Sales: 0.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.66 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 2,612,000
• Free Float: 2,453,000
• Market Cap: $13.10 million
• Optionable: Optionable
• Beta: 1.11